As per the research report, the size of the Europe HIV Diagnostics Market is valued at USD 546 million in 2021 and estimated to be growing at a CAGR of 9.20%, to reach 847.82 million by 2026 during the forecast period 2021 to 2026.
The human immunodeficiency virus (HIV) refers to a kind of retrovirus that causes (AIDS). HIV affects some immune cells and it weakens immune system bringing about loss of capacity to fight against the organisms that causes diseases. HIV spreads through exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV infected. The present situation is like various POC/rapid tests are under clinical advancement and examination in the item pipelines of significant market members and are relied upon to acquire regulatory approval in various local segments of the market. This normal increment in the quantity of item offerings to the worldwide market space is required to fuel the development of the HIV diagnostics industry over the forecast period.
Major factors driving the market are, the technological advancement of disease diagnostic tests, and the foreseen improvement and commercialization of novel, regulatory authorities approved POC and rapid CD4, p24 antigen and EID tests; it is expected that all the major regional market segments will witness an expansion in market demand over the forecast period. There is a need to increase in introducing easily accessible, efficient robust diagnostics tests. Because of the financial resource constrained settings in a huge share of the disease affected regions it is as yet not feasible to perform the current, complex screening, staging and monitoring tests. This is either because of the absence of adequate testing labs or an absence of prepared clinical technicians capable of performing the tests. These limitations of laboratory based testing are a catalyst to the improvement of convenient and simple to execute point of care, rapid tests.
This research report segmented and sub-segmented into the following categories:
Key players operating in the Europe HIV diagnostics Market profiled in this report are Abbott Healthcare, Brsitol-Myers Squibb, Alere Inc., Abbvie Inc., Janssen Therapeutics, Gilead Sciences, Merck & Co. Inc, BD Biosciences, Beckman Coulter, Partec, Sysmex, VIIV Healthcare, Apogee Flow Systems, Mylan inc., PointCare Technologies Inc., Zyomyx Inc., Roche Diagnostics, Qiagen, Siemens Healthcare, and bioMerieux.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Consumables
5.1.2.1 Assays and Kits &Reagents
5.1.2.2 Other Consumables
5.1.3 Instruments
5.1.4 Software & Services
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2 Type
5.2.1 Introduction
5.2.2 Antibody Tests
5.2.2.1 HIV Screening Tests
5.2.2.1.1 Elisa
5.2.2.1.2 Rapid Tests
5.2.2.1.3 Home Access Dried Blood Spots
5.2.2.2 HIV-1 Antibody Confirmatory Tests
5.2.2.2.1 Western Blot Tests
5.2.2.2.2 Indirect Immunofluorescence Assays (IFA)
5.2.2.2.3 Line Immunoassays
5.2.2.2.4 Radio-Immunoprecipitation Assays
5.2.2.3 HIV-2 & Group O Diagnostic Tests
5.2.2.3.1 Blood Antibody Tests
5.2.2.3.2 DBS Tests
5.2.2.3.3 Line ImmunoAssay (HIV2)
5.2.3 Viral Identification Tests
5.2.3.1 p24 Antigen Test
5.2.3.2 Qualitative PCR Tests
5.2.3.3 Viral Culture
5.2.4 CD4 Testing
5.2.5 Viral Load testing
5.2.6 Early Infant Diagnostics
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
5.3 End User
5.3.1 Introduction
5.3.2 Diagnostic Laboratories
5.3.3 Hospitals
5.3.4 Blood Banks
5.3.5 Home Care Settings
5.3.6 Other End Users
5.3.7 Y-o-Y Growth Analysis, By End User
5.3.8 Market Attractiveness Analysis, By End User
5.3.9 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Type
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Type
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Type
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7.Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Siemens Healthineers (A Division of Siemens AG)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Roche Diagnostics (Division of Hoffman La Roche Ltd.)
8.3 Abbott Laboratories &
Related Reports
Apr 2021
